-
2022 ESMO Extranodal NK/T-cell Lymphoma Treatment New Hope? The safety and efficacy of PLM60+ Pecopetase treatment are encouraging!
Time of Update: 2022-10-03
Table 2 PK results (left: total mitoxantrone; Right: Free mitoxantraquinone ( )efficacyEfficacy was assessed in all 31 patients, with a complete response (CR) rate of 61.
Table 2 PK results (left: total mitoxantrone; Right: Free mitoxantraquinone ( )efficacyEfficacy was assessed in all 31 patients, with a complete response (CR) rate of 61.
-
Professor Xu Wei: Seliniso has contributed to improving the treatment status of DLBCL patients!
Time of Update: 2022-10-03
Pervasive large B-cell lymphoma (DLBCL) is a common subtype of highly aggressive and heterogeneous non-Hodgkin lymphoma that is more common in middle-aged and older people. Rituximab plus cyclophospha
-
Micro Classroom No. 11 Professor An Gang: Guidelines for Integrated Diagnosis and Treatment of Tumors in China (CACA)—MM Integrated Diagnosis and Treatment (MDT to HIM) Overview
Time of Update: 2022-10-03
"China Cancer Integrated Diagnosis and Treatment Guidelines" 1 is the authoritative experts of the Chinese Anti-Cancer Association (CACA) over a period of more than 1 year, collectively compiled and c
-
Tuojie Life, Worun Hope To accurately write the miracle of life, Tuoshuwo ® (Aivnibu Film) China Listing Conference · East China Railway Station was successfully held!
Time of Update: 2022-10-03
Fanglin new leaves promote Chen leaves, and thousands of sails compete to make Vientiane new. In recent years, with the development of molecular detection technology and the emergence of precision tar
-
CSH Innovation Forum| Liang Aibin, He Pengcheng, Gu Hongfei, Sun Qiu, Tan Yun invite you to join the academic feast on September 23-25 - the 17th National Hematology Academic Conference of the Chinese Medical Association
Time of Update: 2022-10-03
Looking forward to using the power of medical humanities, doctors and patients can enhance mutual understanding and jointly build a harmonious and warm doctor-patient relationship!Forum of domestic and foreign journal publishing housesSeptember 24, 13:30-17:00Sun Qiu Associate ProfessorWest China Hospital, Sichuan University, Editorial Department of Signal Transduction and Targeted TherapyScientific and technological journals are an important carrier for inheriting human civilization, gathering scientific discoveries and leading the development of science and technology.
-
Studies have revealed the pathologic mechanism of high-altitude thrombosis
Time of Update: 2022-10-03
reveals the pathologic mechanism of highland thrombosisSource: Kunming Institute of Zoology, Chinese Academy of SciencesHigh altitude exposure is an important risk factor for the onset of thrombotic disease.
-
CSH Joint Forum| Ma Jun, Zhu Jun, Huang He, Zhao Donglu, Chen Suning, Wei Hui invite you to join in the academic feast on September 23-25 - the 17th National Hematology Academic Conference of the Chinese Medical Association
Time of Update: 2022-10-03
Listening to the sound of blood and perceiving the rhythm of life, the much-anticipated "17th National Hematology Academic Conference of the Chinese Medical Association" will be grandly opened on Sep
-
"Born of Beauty, Broad and Loving" A "graduation" ceremony for lymphoma patients
Time of Update: 2022-10-03
Ruijin Hematology Zhao Weichen team and patient representatives Pass on the torch and go to the covenant of healing At the beginning of the "graduation" ceremony, Professor Zhao Weicheng said kindly: "Improving the cure rate of blood system diseases such as lymphoma and helping patients to return to society is inseparable from the joint efforts of doctors and patients.
-
ESMO Strikes New Hope for Extranodal NK/T-cell Lymphoma Treatment? The safety and efficacy of PLM60+ Pecopetase treatment are encouraging!
Time of Update: 2022-10-03
Table 2 PK results (left: total mitoxantrone; Right: Free mitoxantraquinone ( ) efficacy Efficacy was assessed in all 31 patients, with a complete response (CR) rate of 61.
-
The world's first CD19 ADC received positive comments from CHMP, expanding the commercial territory!
Time of Update: 2022-10-03
20 September 2022 / eMedClub News/-Recently, ADC Therapeutics and Swedish Orphan Biovitrum AB jointly announced that the European Medicines Agency's Committee on Medicines for Human Use (CHMP) has announced that it has taken a positive opinion on the use of the CD19-targeted antibody-coupled drug Zynlonta in the treatment of recurrent or refractory diffuse large B-cell lymphoma (DLBCL).
-
[Lancet Oncol Review] CNS prevention of diffuse large B-cell lymphoma
Time of Update: 2022-10-02
Involvement of the CNS is an uncommon and usually fatal event, with about 5% of patients with systemic diffuse large B-cell lymphoma (DLBCL) having a CNS recurrence during or shortly after initial tre
-
Case report: Successful allogeneic stem cell transplantation in children with novel GATA2-deficient B-cell acute lymphoblastic leukemia
Time of Update: 2022-10-02
Here, we describe a successful bone marrow transplant of a carrier of the new GATA2 pathogenic variant who was diagnosed with immunodeficiency several years after completing treatment with B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
-
Big coffee interview with Professor Wan Dingming: Treatment and management of paroxysmal nocturnal hemoglobinuria
Time of Update: 2022-10-02
The application of C5 complement inhibitors in PNH therapy has yet to be popularized PNH is a very rare acquired hematopoietic stem cell clonal disease with an incidence of less than one in 100,000 and common clinical manifestations of anemia and hemoglobinuria.
-
Interview with Professor Jiang Zhongxing: The Challenges and Prospects of the Treatment of Aplastic Anemia
Time of Update: 2022-10-02
Fenghua "Zheng" Mao, the exhibition "red" map, sponsored by the Chinese Medical Association and the Chinese Medical Association Hematology Branch, hosted by the Henan Provincial Medical Association, a
-
【AJH】Preliminary efficacy and safety of Ricky Orence injection in the treatment of relapsed/refractory follicular lymphoma in China
Time of Update: 2022-10-02
The authors recently analyzed the r/r FL cohort (including dose-increasing and dose-extended cohorts) in the study receiving 100 × 106 or 150 ×106 CAR-T cells, with the aim of evaluating the initial efficacy and safety of patients treated r/r FL with Ricky Orensey injection.
-
First acquaintance with thalassemia
Time of Update: 2022-10-02
Figure 2 (Regis staining X1000)According to the results of routine blood and peripheral blood smear examination, it is recommended to prescribe relevant tests such as iron metabolism, hemoglobin electrophoresis, erythrocyte osmotic fragility experiment and geopoor genetic detection.
-
Clin Cancer Res: Venetok plus azacitidine for AML with low cytogenetic risk
Time of Update: 2022-10-02
For patients at low cytogenetic risk of TP53 wild-type, Vinetok plus azacitine significantly improved the compound response rate (70% vs 23%) compared with azacitine monotherapy.
For patients at low cytogenetic risk of TP53 wild-type, Vinetok plus azacitine significantly improved the compound response rate (70% vs 23%) compared with azacitine monotherapy.
-
International Hematological Tumor Month Professor Hu Yu: Seeing the moon from the clouds, leading the targeting, and viewing the development trend of AML management of FLT3 mutation from the perspective of the change of guidelines
Time of Update: 2022-10-02
In addition, the widespread clinical application of a variety of innovative FLT3 inhibitors such as geretinib in recent years has significantly improved the survival of AML patients, which may be the reason why the FLT3 higher allele specific mutation has changed from high-risk to medium-threatening; The addition of multiple poorly prognostic genes also suggests that AML prognostic stratification is still evolving.
-
【JCO Editorial】Is the treatment of diffuse large B-cell lymphoma getting smarter?
Time of Update: 2022-10-02
In early August, the Journal of Clinical Oncology reported on a researcher-initiated, single-armed, Phase II Smart Start study that explored a new combination regimen for the initial treatment of diffuse large B-cell lymphoma, namely rituximab, lenalidomide, and ibratinib (RLI).
-
Fanconi anemia: signs and symptoms, etiology, epidemiology, diagnosis and treatment
Time of Update: 2022-10-02
Affected people are at increased risk of developing bone marrow hematopoietic cell carcinoma, called acute myeloid leukemia (AML), or tumors of the head, neck, skin, gastrointestinal system, or genital tract.
